PI3K pathway-directed therapeutic strategies in cancer

Roshan Agarwal, Mark Carey, Bryan Hennessy, Gordon Mills

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.

Original languageEnglish (US)
Pages (from-to)615-628
Number of pages14
JournalCurrent Opinion in Investigational Drugs
Volume11
Issue number6
StatePublished - Jun 1 2010
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinases
Pharmaceutical Preparations
Neoplasms
Therapeutics
Clinical Trials

Keywords

  • Akt
  • Cancer
  • Drug development
  • Growth factor signaling
  • Phase I clinical trial
  • PI3K
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

PI3K pathway-directed therapeutic strategies in cancer. / Agarwal, Roshan; Carey, Mark; Hennessy, Bryan; Mills, Gordon.

In: Current Opinion in Investigational Drugs, Vol. 11, No. 6, 01.06.2010, p. 615-628.

Research output: Contribution to journalReview article

Agarwal, R, Carey, M, Hennessy, B & Mills, G 2010, 'PI3K pathway-directed therapeutic strategies in cancer', Current Opinion in Investigational Drugs, vol. 11, no. 6, pp. 615-628.
Agarwal, Roshan ; Carey, Mark ; Hennessy, Bryan ; Mills, Gordon. / PI3K pathway-directed therapeutic strategies in cancer. In: Current Opinion in Investigational Drugs. 2010 ; Vol. 11, No. 6. pp. 615-628.
@article{bf9d58ed392246229072ea71b0622cab,
title = "PI3K pathway-directed therapeutic strategies in cancer",
abstract = "PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.",
keywords = "Akt, Cancer, Drug development, Growth factor signaling, Phase I clinical trial, PI3K, Targeted therapy",
author = "Roshan Agarwal and Mark Carey and Bryan Hennessy and Gordon Mills",
year = "2010",
month = "6",
day = "1",
language = "English (US)",
volume = "11",
pages = "615--628",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - PI3K pathway-directed therapeutic strategies in cancer

AU - Agarwal, Roshan

AU - Carey, Mark

AU - Hennessy, Bryan

AU - Mills, Gordon

PY - 2010/6/1

Y1 - 2010/6/1

N2 - PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.

AB - PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.

KW - Akt

KW - Cancer

KW - Drug development

KW - Growth factor signaling

KW - Phase I clinical trial

KW - PI3K

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77952936573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952936573&partnerID=8YFLogxK

M3 - Review article

C2 - 20496256

AN - SCOPUS:77952936573

VL - 11

SP - 615

EP - 628

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 6

ER -